SIGA Technologies Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Diem Nguyen

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	3yrs

Recent management updates

Recent updates

SIGA Technologies, Inc. (NASDAQ:SIGA) Stock Rockets 64% But Many Are Still Ignoring The Company

Mar 31

Siga Technologies: Preparing For A Contingency If Tomorrow Comes

Mar 25

Shareholders Can Be Confident That SIGA Technologies' (NASDAQ:SIGA) Earnings Are High Quality

Mar 19

SIGA to activate first trial sites for monkeypox therapy in U.K. next week – Bloomberg

Aug 17

Estimating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)

Aug 12

SIGA to deliver $26M of monkeypox therapy to U.S. in 2023 after option exercise

Aug 09

SIGA Technologies: Unjustified Selloff, Loading The Boat, Best Monkeypox Play

Aug 01

SIGA Technologies: Buy Monkeypox

Jul 25

Siga Technologies receives approval from UK for tecovirimat

Jul 08

SIGA Technologies: Solid Business With Means To Address Monkeypox Outbreak

May 27

SIGA Technologies: There's An Assured Market For A Smallpox Vaccine

Dec 12

It's Probably Less Likely That SIGA Technologies, Inc.'s (NASDAQ:SIGA) CEO Will See A Huge Pay Rise This Year

Jun 08

SIGA Technologies: Biodefense Pharma Unlocks New Value Abroad For TPOXX

Apr 28

Introducing SIGA Technologies (NASDAQ:SIGA), The Stock That Soared 880% In The Last Five Years

Feb 22

We're Not So Sure You Should Rely on SIGA Technologies' (NASDAQ:SIGA) Statutory Earnings

Feb 02

SIGA Technologies +4% AH, announces Canada contract to purchase up to ~$33M of oral TPOXX

Jan 13

Is SIGA Technologies, Inc.'s (NASDAQ:SIGA) Latest Stock Performance Being Led By Its Strong Fundamentals?

Jan 12

Read This Before Buying SIGA Technologies, Inc. (NASDAQ:SIGA) Shares

Dec 22

Getting In Cheap On SIGA Technologies, Inc. (NASDAQ:SIGA) Is Unlikely

Dec 04

CEO

Diem Nguyen (51 yo)

less than a year

Tenure

Dr. Diem Nguyen, Ph D., M.B.A., is Chief Executive Officer and Director of SIGA Technologies, Inc. from January 27, 2024. She serves as an Independent Director of Candel Therapeutics, Inc. since July 2021....

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Daniel Luckshire	Executive VP	13.2yrs	US$1.38m	0.35% $ 2.2m
Dennis Hruby	Executive VP & Chief Scientific Officer	23.8yrs	US$1.41m	0.21% $ 1.3m
Jay Varma	Executive VP	less than a year	US$193.49k	0% $ 0
Diem Nguyen	CEO & Director	less than a year	no data	no data
Tove Bolken	Senior VP of Operations & Chief Supply Chain Officer	no data	no data	no data
Herb Vloedman	Senior VP & Chief Information Officer	no data	no data	no data
Lawrence Miller	General Counsel	less than a year	no data	0.043% $ 267.0k

0.6yrs

Average Tenure

51.5yo

Average Age

Experienced Management: SIGA's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Jay Varma	Executive VP	1.4yrs	US$193.49k	0% $ 0
Diem Nguyen	CEO & Director	less than a year	no data	no data
Jaymie Durnan	Independent Director	3.8yrs	US$210.27k	0.058% $ 356.1k
Joseph Marshall	Independent Director	15.1yrs	US$225.27k	0.28% $ 1.7m
Julian Nemirovsky	Independent Director	3.3yrs	US$212.77k	0.037% $ 226.5k
Harold Ford	Independent Director	1.4yrs	US$193.49k	0% $ 0
Gary Nabel	Independent Director	2.8yrs	US$205.76k	0.037% $ 226.5k
Evan Knisely	Director	no data	no data	0.014% $ 86.7k
Holly Phillips	Independent Director	3.1yrs	US$207.99k	0.037% $ 226.5k

3.0yrs

Average Tenure

52.5yo

Average Age

Experienced Board: SIGA's board of directors are not considered experienced ( 3 years average tenure), which suggests a new board.

SIGA Technologies Management

Management criteria checks 0/4

Key information

Recent management updates

High number of new directors

Siga Technologies, Inc. Appoints Diem Nguyen to the Board of Directors

SIGA Technologies, Inc. Appoints Jay K. Varma as EVP and Chief Medical Officer

SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023

High number of new directors

SIGA Technologies, Inc. Announces Directorate Appointments

Recent updates

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 17%

SIGA Technologies, Inc. (NASDAQ:SIGA) Stock Rockets 64% But Many Are Still Ignoring The Company

Siga Technologies: Preparing For A Contingency If Tomorrow Comes

Shareholders Can Be Confident That SIGA Technologies' (NASDAQ:SIGA) Earnings Are High Quality

Investor sentiment improves as stock rises 63%

Upcoming dividend of US$0.60 per share

Full year 2023 earnings: EPS and revenues miss analyst expectations

Siga Technologies, Inc. Declares A Special Cash Dividend, Payable on April 11, 2024

SIGA Technologies, Inc. to Report Q4, 2023 Results on Mar 12, 2024

The Price Is Right For SIGA Technologies, Inc. (NASDAQ:SIGA)

High number of new directors

New major risk - Revenue and earnings growth

Siga Technologies, Inc. Appoints Diem Nguyen to the Board of Directors

Third quarter 2023 earnings released: US$0.006 loss per share (vs US$0.45 profit in 3Q 2022)

SIGA Technologies, Inc. to Report Q3, 2023 Results on Nov 07, 2023

SIGA Technologies, Inc. Appoints Jay K. Varma as EVP and Chief Medical Officer

Second quarter 2023 earnings released: US$0.04 loss per share (vs US$0.028 profit in 2Q 2022)

SIGA Technologies, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Inaugural dividend of US$0.45 per share

First quarter 2023 earnings released: US$0.013 loss per share (vs US$0.005 loss in 1Q 2022)

SIGA Technologies, Inc. Declares a Special Cash Dividend, Payable on June 1, 2023

Investor sentiment deteriorates as stock falls 18%

Full year 2022 earnings: EPS and revenues miss analyst expectations

SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023

Investor sentiment improved over the past week

Do SIGA Technologies' (NASDAQ:SIGA) Earnings Warrant Your Attention?

High number of new directors

SIGA Technologies, Inc. Announces Directorate Appointments

Third quarter 2022 earnings released: EPS: US$0.45 (vs US$0.042 loss in 3Q 2021)

SIGA Technologies, Inc. to Report Q3, 2022 Results on Nov 03, 2022

SIGA Technologies, Inc. Provides Update on Progress in Clinical Trials to Assess Use of Tpoxx ® (Tecovirimat) for Treatment of Monkeypox

SIGA Technologies secures new contract awarded to procure up to $10.7M of TPOXX

Investor sentiment deteriorated over the past week

Siga monkeypox therapy undergoes NIH-led late-stage trial

Investor sentiment deteriorated over the past week

Scientists behind key COVID study run monkeypox trial for SIGA therapy

Now 21% undervalued

SIGA to activate first trial sites for monkeypox therapy in U.K. next week – Bloomberg

Estimating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)

SIGA to deliver $26M of monkeypox therapy to U.S. in 2023 after option exercise

James Antal Provides Notice to SIGA Technologies, Inc. of His Resignation from the Board of Directors

Second quarter 2022 earnings released: EPS: US$0.028 (vs US$0.002 in 2Q 2021)

SIGA Technologies: Unjustified Selloff, Loading The Boat, Best Monkeypox Play

SIGA Technologies, Inc. to Report Q2, 2022 Results on Aug 04, 2022

SIGA Technologies: Buy Monkeypox

Investor sentiment improved over the past week

SIGA Technologies Receives Approval from UK for Tecovirimat

Siga Technologies receives approval from UK for tecovirimat

SIGA Technologies, Inc.(NasdaqGM:SIGA) dropped from Russell 2000 Growth-Defensive Index

Investor sentiment improved over the past week

Independent Director exercised options and sold US$70k worth of stock

Investor sentiment improved over the past week

SIGA Technologies: Solid Business With Means To Address Monkeypox Outbreak

SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS exceeds analyst expectations

SIGA Technologies, Inc. Declares a Special Dividend of the Company, Payable on June 2, 2022

High number of new directors

SIGA Technologies, Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

SIGA Technologies, Inc. Announces Start of Tpoxx® Post-Exposure Prophylactic Clinical Trials

SIGA Technologies, Inc. Announces Start of Tpoxx® Post-Exposure Prophylactic Clinical Trials

SIGA Technologies, Inc Receives Approval from the European Medicines Agency for Tecovirimat

SIGA Technologies: There's An Assured Market For A Smallpox Vaccine

Independent Director recently sold US$235k worth of stock

SIGA Technologies, Inc. Announces Health Canada Regulatory Approval of Oral Tpoxx

Investor sentiment improved over the past week

Third quarter 2021 earnings released: US$0.042 loss per share (vs US$0.31 profit in 3Q 2020)